IP Verse

Dosage Regimen For A S1P Receptor Agonist

Patent No. EP3409274 (titled "Dosage Regimen For A S1P Receptor Agonist") was filed by Novartis on Dec 21, 2009. The application was issued on Nov 20, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPAug 18, 2020-
VON SEEBACHAug 18, 2020HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3409274

NOVARTIS
Application Number
EP18179301A
Filing Date
Dec 21, 2009
Status
Revoked
Dec 6, 2024
Publication Date
Nov 20, 2019
External Links
Slate, Register , Google Patents